Bladder cancer is the 6th most common cancer in the USA and the 4th most common amongst Veterans with over 80,000 new cases diagnosed annually. The most effective way to treat Bladder Cancer nowadays is via tumor ablation. However, this method misses many tumors in the microscopic scale. Fullerene-Antibody Conjugate Energetic Nanoparticles (FACE-NP) would be the first of its kind to allow for cancer-specific ablative therapy at the microscopic level without affecting neighboring healthy cells. FACE-NP works by targeting and binding only to the over expressed proteins in the tumor site. Once locked on, they are activated with a low-powered laser that triggers a localized tumor ablation at the microscopic level without affecting normal cells. In this study, the chemical structure and composition of FACE-NP were characterized via Fourier Transform Infrared (FTIR) and Thermogravimetric Analysis (TGA). Additionally, FACE-NP were also synthesized via reflux reaction to illustrate its reproducibility and manufacturing.